PUBLISHED DATE : Nov 2020 | Pages : 263
Fill out your details & get your free sample
Drug-coated Balloons Market Size, Share, Trends Analysis Report by Indication (PAD, CAD, and Others), Drug Type (Paclitaxel and Sirolimus), End-user (Hospitals, Ambulatory Care Settings, and Freestanding Cath Labs), and Geography (APAC, North America, Europe, Latin America, and the Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Share & Forecast, 2020–2025
263 Pages
51 Tables
120 Charts
5 Regions
19 Countries
28 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZE (REVENUE) | USD 1.5 BILLION (2025) |
| CAGR | 15% (2020–2025) |
| Base Year | 2019 |
| Forecast Year | 2020–2025 |
| Market Segments | Indication (PAD, CAD, and Others), Drug Type (Paclitaxel and Sirolimus), End-user (Hospitals, Ambulatory Care Settings, and Freestanding Cath Labs) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, Israel, and Saudi Arabia |
The global drug-coated balloons market size to cross USD 1.5 billion by 2025, growing at a CAGR of 15% during the forecast period. The global drug-coated balloons market is one of the fastest-growing segments in the cardiovascular devices market. The market is growing significantly due to the surge in incidence/prevalence of cardiovascular diseases, especially peripheral artery and coronary artery diseases across the globe.
Cardiovascular diseases are characterized by coronary artery disease (CAD) and peripheral artery disease (PAD). PAD is the third leading cause of atherosclerotic vascular morbidity, which affects approximately 200 million people worldwide. Besides, about 3.8 million men and 3.4 million women die from CAD per year. DCB technology is highly innovative and expected to influence the existing treatment modalities of vascular diseases and ESRD to a great extent. The introduction of DCBs has been a significant breakthrough in the cardiovascular industry with great high potential in terms of minimizing restenosis.
The peripheral artery disease (PAD) segment accounted for a share of over 81% in 2019, and it is expected to retain its market dominance during the forecast period. The adoption of drug-coated balloons (DCB) for treating PAD is growing rapidly, primarily due to the availability of positive clinical data, supporting the safety and efficacy of DCB technology. The segment accounts for the largest share as the majority of DCB devices are commercially available for PAD indication. However, despite high potential growth opportunities for treating PAD, the recent COVID-19 pandemic has caused unprecedented challenges to perform PCI procedures. The spread of the virus has triggered disruption across the globe with lockdowns, travel bans, and ban on large gatherings such as major cardiac scientific society meetings being canceled, with substantial pressure on the health care services across the world.
In 2019, the coronary artery disease (CAD) segment constituted over 11% of the global drug-coated balloons market. The market is growing at a significant rate and is likely to grow during the forecast period. The growth in the CAD patient pool globally is a major key factor for the growth of the segment. Cardiovascular diseases, especially CAD, are recognized as the leading cause of death globally. Moreover, a high prevalence of CAD in developing countries such as India, a significant health challenge, is likely to influence the segment growth.
The paclitaxel segment accounts for the maximum market share as these devices are safe and effective in treating CVDs, AV, and urological disorders. Paclitaxel-coated balloon (PCB) technology has emerged as a promising therapeutic alternative in the PCI procedure, especially for CVDs. The majority of commercially available DCBs are paclitaxel-coated. Paclitaxel-coated balloons are clinically proven, reducing the risk of restenosis after angioplasty of atherosclerotic femoropopliteal lesions. This is increasing their demand among healthcare professionals. In 2019, the sirolimus segment accounted for over 3% of the market. This segment is a new generation of DCBs, where balloons are coated with a medicine called sirolimus. There are a few commercially available sirolimus DCBs. Thus the contribution of the segment is low than paclitaxel-coated balloons.
The global drug-coated balloons market is segmented into hospitals, freestanding CATH labs, and ASCs. Healthcare professionals in hospitals use DCBs mainly for cardiovascular disorders, including AV interventions, urological, and neurovascular procedures. The segment is growing at a healthy rate due to the high adoption of the latest generation DCBs. A majority of patients with an increased risk of cardiovascular diseases prefer visiting hospitals for treatment due to advanced infrastructure facilities available in major private and public hospitals, the segment is expected to grow significantly.
In 2019, the freestanding CATH labs' end-user segment accounted for over 28% share. Freestanding CATH labs offer several advantages for patients that need endovascular procedures and significant financial benefits to health care professionals. Europe and France have the highest number of freestanding CATH labs, with around 2.9 freestanding CATH labs per one million. The presence of favorable reimbursement procedures is an essential factor contributing to the segment growth. These labs use cutting edge technology to perform several heart procedures. Continued technological innovations are helping freestanding CATH labs to perform minimally invasive procedures, which is increasing their market revenue.
Frequently Asked Questions
What is the global drug-coated balloons market size and growth rate during the forecast period?
The global drug-coated balloons market is expected to reach USD 1.5 Billion by 2025, growing at a CAGR of close to 16%.
What are the factors impacting the growth of the drug-coated balloons market share?
Factors such as promising outcomes of drug-coated balloons, increasing focus on investigational drug-coated balloons, and growing application of DCBs are major factors influencing the market growth
What is the growth of North America drug-coated balloons market during the forecast period?
North America is expected to witness the highest growth rate over the forecast period with over 16% in the global market.
Who are the leading vendors in the drug-coated balloons market?
Hillrom, Medtronic, BD, Koninklijke Philips, Boston Scientific, and B. Braun Melsungen are the key vendors in the market in terms of technology, safety features, regulatory approvals, marketing strategies, and distribution channels.
What is the impact of COVID-19 pandemic on the global market?
With the spread of the COVID-19 pandemic, several hospitals, CATH labs, and ASCs have experienced a rapid decline in the volume of elective cardiology procedures.
The drug-coated balloons market by revenue is expected to grow at a CAGR of 15% during the period 2019–2025.
Investigational Companies
By Indication
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the Study
4.4 Market Segments
4.4.1 Market Segmentation by Indication
4.4.2 Market Segmentation by Drug Type
4.4.3 Market Segmentation by End-user
4.4.4 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Drug Coated Balloons (DCBS): An Overview
7.1.1 Background
7.1.2 Use of DCBs
8 Market Opportunities & Trends
8.1 Increased Application of DCBs to Treat Medical Disorders
8.2 Promising Investigational Drug-Coated Balloons
8.3 Emergence of New Generation DCBs
9 Market Growth Enablers
9.1 Global Increase in Target Patient Pool
9.2 Increasing Demand for DCBs Due to Promising Outcomes
9.3 Increased Focus on Generating Abundant Clinical Data
9.4 New Product Approvals/Launches
10 Market Restraints
10.1 Presence of Alternative Treatment Procedures
10.2 Stringency in Regulatory Approvals
10.3 Lack of Reimbursement Coverage For DCBs
11 Market Landscape
11.1 Market Overview
11.2 COVID-19 Impact on Global Drug-Coated Balloons Market
11.3 Market Size & Forecast
11.3.1 Geographic Insights
11.3.2 Indication Insights
11.3.3 Drug Type
11.3.4 End-User Insights
11.4 Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Drug-coated Balloons Market by Indication
12.1 Snapshot & Growth Engine
12.2 Overview
12.3 PAD
12.3.1 Overview
12.3.2 Size & Forecast
12.4 CAD
12.4.1 Overview
12.4.2 Size & Forecast
12.5 Others
12.5.1 Overview
12.5.2 Size & Forecast
13 Drug-coated Balloons Market by Drug Type
13.1 Snapshot & Growth Engine
13.2 Overview
13.3 Paclitaxel
13.3.1 Overview
13.3.2 Size & Forecast
13.4 Sirolimus
13.4.1 Overview
13.4.2 Size & Forecast
14 Drug-coated Balloons Market by End-User
14.1 Snapshot & Growth Engine
14.2 Overview
14.3 Hospitals
14.3.1 Overview
14.3.2 Size & Forecast
14.4 Freestanding Cath Labs
14.4.1 Overview
14.4.2 Size & Forecast
14.5 ASCs
14.5.1 Overview
14.5.2 Size & Forecast
15 Drug-coated Balloons Market by Geography
15.1 Snapshot & Growth Engine
15.2 Geographic Overview
16 North America
16.1 Overview
16.2 Size & Forecast
16.3 Key Countries
16.3.1 US: Drug-coated Balloons Market Size & Forecast
16.3.2 Canada: Size & Forecast
17 Europe
17.1 Overview
17.2 Size & Forecast
17.3 Key Countries
17.3.1 Germany: Drug-coated Balloons Market Size & Forecast
17.3.2 France: Size & Forecast
17.3.3 UK: Drug-coated Balloons Market Size & Forecast
17.3.4 Italy: Size & Forecast
17.3.5 Spain: Drug-coated Balloons Market Size & Forecast
18 APAC
18.1 Overview
18.2 Size & Forecast
18.4 Key Countries
18.4.1 Japan: Size & Forecast
18.4.2 China: Drug-coated Balloons Market Size & Forecast
18.4.3 Australia: Size & Forecast
18.4.4 South Korea: Drug-coated Balloons Market Size & Forecast
18.4.5 India: Size & Forecast
19 Latin America
19.1 Overview
19.2 Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Drug-coated Balloons Market Size & Forecast
19.3.2 Mexico: Size & Forecast
19.3.3 Argentina: Drug-coated Balloons Market Size & Forecast
20 Middle East & Africa
20.1 Overview
20.2 Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Drug-coated Balloons Market Size & Forecast
20.3.2 Saudi Arabia: Size & Forecast
20.3.3 Israel: Drug-coated Balloons Market Size & Forecast
20.3.4 South Africa: Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Medtronic
21.2.2 BD
21.2.3 Koninklijke Philips
21.2.4 Boston Scientific
21.2.5 B. Braun Melsungen
22 Key Company Profiles
22.1 Medtronic
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 BD
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Koninklijke Philips
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Boston Scientific
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 B. Braun Melsungen
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
23 OTHER PROMINENT VENDORS
23.1 Aachen Resonance
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Acotec Scientific
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 AR Baltic Medical
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 Biosensors International Group
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 Biotronik
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Cardionovum
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 Concept Medical
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 Eucatech
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Endocor
23.9.1 Business Overview
23.9.2 Product Offerings
23.1 Hexacath
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Ivascular
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 M.A. Med Alliance
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Meril Life Sciences
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Nano Therapeutics
23.14.1 Business Overview
23.14.2 Product Offerings
23.15 QT Vascular
23.15.1 Business Overview
23.15.2 Product Offerings
23.16 RD Global-Invamed
23.16.1 Business Overview
23.16.2 Product Offerings
23.17 Stentys
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 Surmodics
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 Terumo
23.19.1 Business Overview
23.19.2 Product Offerings
23.2 Urotronic
23.20.1 Business Overview
23.20.2 Product Offerings
23.21 Wellinq
23.21.1 Business Overview
23.21.2 Product Offerings
24 Investigational Companies
24.1 Micell Technologies
24.1.1 Business Overview
24.1.2 Investigational Products
24.2 Orchestra Biomed
24.2.1 Business Overview
24.2.2 Investigational Products
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Indication
26.2 Drug Type
26.3 End-User
26.4 Geography
27 Appendix
27.1 Abbreviations
Exhibit 1 Segmentation of Global Drug-coated Balloons Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Key Application Areas of DCBs
Exhibit 4 Market Dynamics of DCBs
Exhibit 5 Global Drug-coated Balloons Market by Geography 2019 (%)
Exhibit 6 Global Drug-coated Balloons Market by Indication 2019 (%)
Exhibit 7 Impact of Increased Application of DCBs to Treat Medical Disorders
Exhibit 8 Impact of Promising Investigational Drug-coated Balloons
Exhibit 9 Impact of Emergence of New Generation DCBs
Exhibit 10 Impact of Global Increase in Target Patient Pool
Exhibit 11 Impact of Increasing Demand for DCBs due to Promising Outcomes
Exhibit 12 Comparison of Vascular Restenosis in DCBs with Other Devices
Exhibit 13 Comparison of Freedom from Target Lesion Revascularization in DCBs with Other Devices
Exhibit 14 Repeat Procedure Rates for Various PAD Treatment Devices
Exhibit 15 Impact of Increased Focus on Generating Abundant Clinical Data
Exhibit 16 Impact of New Product Approvals/Launches
Exhibit 17 Impact of Presence of Alternative Treatment Procedures
Exhibit 18 Common Alternative Treatment Options to DCBs
Exhibit 19 Impact of Stringency in Regulatory Approvals
Exhibit 20 Major Actions/Sanctions Imposed on Manufacturers by Regulatory Bodies
Exhibit 21 Impact of Lack of Reimbursement Coverage for DCBs
Exhibit 22 COVID-19 Impact on Management of Patients with Acute Coronary Diseases
Exhibit 23 Global Drug-coated Balloons Market 2019–2025 ($ million)
Exhibit 24 Global Drug-coated Balloons Market by Geography
Exhibit 25 Global Drug-coated Balloons Market by Indication
Exhibit 26 Global Drug-coated Balloons Market by Drug Type
Exhibit 27 Global Drug-coated Balloons Market by End-user
Exhibit 28 Five Forces Analysis 2019
Exhibit 29 Incremental Growth by Indication 2019 & 2025
Exhibit 30 The Global Drug-coated Balloons Market by Indication
Exhibit 31 Global Market by Indication: Incremental Growth
Exhibit 32 Global Market by Indication: Absolute Growth
Exhibit 33 Global Drug-coated Balloons Market for PAD: Incremental & Absolute Growth
Exhibit 34 Key Benefits Offered by DCBs Compared to Plain Balloon Angioplasty
Exhibit 35 Global Market for PAD 2019–2025 ($ million)
Exhibit 36 Global Drug-coated Balloons Market for CAD: Incremental & Absolute Growth
Exhibit 37 Global Market for CAD 2019–2025 ($ million)
Exhibit 38 Global Drug-coated Balloons Market for Others: Incremental & Absolute Growth
Exhibit 39 Global Market for Other Indications 2019–2025 ($ million)
Exhibit 40 Incremental Growth by Drug Type 2019 & 2025
Exhibit 41 The Global Drug-coated Balloons Market by Drug Type
Exhibit 42 Global Market by Product: Incremental Growth
Exhibit 43 Global Market by Product: Absolute Growth
Exhibit 44 Global Paclitaxel-coated Balloons Market: Incremental & Absolute Growth
Exhibit 45 Global Filter Paclitaxel-coated Balloons Market 2019–2025 ($ million)
Exhibit 46 Global Sirolimus-coated Balloons Market: Incremental & Absolute Growth
Exhibit 47 Global Filter Sirolimus-coated Balloons Market 2019–2025 ($ million)
Exhibit 48 Incremental Growth by End-user 2019 & 2025
Exhibit 49 The Global Drug-coated Balloons Market by End-user
Exhibit 50 Global Market by End-user: Incremental Growth
Exhibit 51 Global market by End-user: Absolute Growth
Exhibit 52 Global Market by Hospitals: Incremental & Absolute Growth
Exhibit 53 Global Market by Hospitals 2019–2025 ($ million)
Exhibit 54 Global Market by Freestanding CATH Labs: Incremental & Absolute Growth
Exhibit 55 Global Market by Freestanding CATH Labs 2019–2025 ($ million)
Exhibit 56 Global Market by ASCs: Incremental & Absolute Growth
Exhibit 57 Global Market by ASCs 2019–2025 ($ million)
Exhibit 58 Incremental Growth by Geography 2019 & 2025
Exhibit 59 The Global Drug-coated Balloons Market by Geography
Exhibit 60 Global Market by Geography 2019: Key Countries ($ million)
Exhibit 61 Global Market by Geography: Incremental Growth
Exhibit 62 Global Market by Geography: Absolute Growth
Exhibit 63 Global Drug-coated Balloons Market in North America 2019
Exhibit 64 North America Market: Absolute & Incremental Growth
Exhibit 65 Market in North America 2019–2025 ($ million)
Exhibit 66 Incremental Growth in North America 2019 & 2025
Exhibit 67 Market in US 2019–2025 ($ million)
Exhibit 68 Market in Canada 2019–2025 ($ million)
Exhibit 69 Europe Drug-coated Balloons Market: Key Countries 2019
Exhibit 70 Market in Europe: Incremental & Absolute Growth
Exhibit 71 Number of PCI Procedures Performed with DCBs across Europe in 2016 (per million people)
Exhibit 72 Market in Europe 2019–2025 ($ million)
Exhibit 73 Incremental Growth in Europe 2019 & 2025
Exhibit 74 Market in Germany 2019–2025 ($ million)
Exhibit 75 Market in France 2019–2025 ($ million)
Exhibit 76 Market in UK 2019–2025 ($ million)
Exhibit 77 Market in Italy 2019–2025 ($ million)
Exhibit 78 Market in Spain 2019–2025 ($ million)
Exhibit 79 APAC Drug-coated Balloons Market in 2019
Exhibit 80 APAC Market: Incremental & Absolute Growth
Exhibit 81 Market in APAC 2019–2025 ($ million)
Exhibit 82 Population Demographics in APAC
Exhibit 83 Health Access & Quality Index Score for Key APAC Countries 2016
Exhibit 84 Incremental Growth in APAC 2019 & 2025
Exhibit 85 Market in Japan 2019–2025 ($ million)
Exhibit 86 Market in China 2019–2025 ($ million)
Exhibit 87 Market in Australia 2019–2025 ($ million)
Exhibit 88 Market in South Korea 2019–2025 ($ million)
Exhibit 89 Market in India 2019–2025 ($ million)
Exhibit 90 Latin America Drug-coated Balloons Market 2019
Exhibit 91 Market in Latin America: Incremental & Absolute Growth
Exhibit 92 Market in Latin America 2019–2025 ($ million)
Exhibit 93 Incremental Growth in Latin America 2019 & 2025
Exhibit 94 Market in Brazil 2019–2025 ($ million)
Exhibit 95 Market in Mexico 2019–2025 ($ million)
Exhibit 96 Market in Argentina 2019–2025 ($ million)
Exhibit 97 Middle East & Africa Drug-coated Balloons Market in 2019
Exhibit 98 Middle East & Africa Market: Incremental & Absolute Growth
Exhibit 99 Market in Middle East & Africa 2019–2025 ($ million)
Exhibit 100 Incremental Growth in Middle East & Africa 2019 & 2025
Exhibit 101 Market in Turkey 2019–2025 ($ million)
Exhibit 102 Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 103 Market in Israel 2019–2025 ($ million)
Exhibit 104 Market in South Africa 2019–2025 ($ million)
Exhibit 105 Market Share (2019)
Exhibit 106 Medtronic: R&D Expenditure 2017−2019 ($ million)
Exhibit 107 Medtronic: Revenue by Segment 2018 & 2019 ($ million)
Exhibit 108 Medtronic: Revenue by Geography 2019 (%)
Exhibit 109 BD: R&D Expenditure 2017−2019 ($ million)
Exhibit 110 BD: Revenue by Business Segments 2018 & 2019 ($ million)
Exhibit 111 BD: Revenue by Geography 2019 (%)
Exhibit 112 Koninklijke Philips: R&D Expenditure 2017−2019 ($ million)
Exhibit 113 Koninklijke Philips: Revenue by Segments 2018 & 2019 ($ million)
Exhibit 114 Koninklijke Philips: Revenue by Geography 2019 (%)
Exhibit 115 Boston Scientific: R&D Expenditure 2017−2019 ($ million)
Exhibit 116 Boston Scientific: Revenue by Business Segments 2018 & 2019 ($ million)
Exhibit 117 Boston Scientific: Revenue by Geography 2019 (%)
Exhibit 118 B. Braun Melsungen: R&D Spend 2017−2019 ($ million)
Exhibit 119 B. Braun Melsungen: Revenue by Segment 2018 & 2019 ($ million)
Exhibit 120 Braun Melsungen: Revenue by Geography 2019 (%)
LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2019
Table 3 Extended Indications for DCBs
Table 4 Major Pipeline DCBs
Table 5 Major Latest-generation DCBs Available in Market
Table 6 Global Drug-coated Balloons Market: Major Clinical Trials Conducted on DCBs by Various Vendors
Table 7 Product Approvals/Launches in Global Drug-coated Balloons Market 2016−2020
Table 8 Significant Players Offering DCBs for PAD Indications
Table 9 Significant Players Offering DCBs for CAD Intervention
Table 10 Significant Players Offering DCBs for Others
Table 11 Key Paclitaxel-coated Balloons Offered by Significant Players
Table 12 Key Sirolimus-coated Balloons Offered by Significant Players
Table 13 Provincial Reimbursement Policy in China
Table 14 Competitive Structure of the Global Drug-coated Balloons Market
Table 15 Global Drug-coated Balloons Market: Vendors Ranking 2019
Table 16 Medtronic: Major Product Offerings
Table 17 BD: Major Product Offerings
Table 18 Koninklijke Philips: Major Product Offerings
Table 19 Boston Scientific: Major Product Offerings
Table 20 B. Braun Melsungen: Major Product Offerings
Table 21 Aachen Resonance: Major Product Offerings
Table 22 Acotec Scientific: Major Product Offerings
Table 23 AR Baltic Medical: Major Product Offerings
Table 24 Biosensors International Group: Major Product Offerings
Table 25 BIOTRONIK: Major Product Offerings
Table 26 Cardionovum: Major Product Offerings
Table 27 Concept Medical: Major Product Offerings
Table 28 eucatech: Major Product Offerings
Table 29 ENDOCOR: Major Product Offerings
Table 30 HEXACATH: Major Product Offerings
Table 31 iVascular: Major Product Offerings
Table 32 M.A. Med Alliance: Major Product Offerings
Table 33 Meril Life Sciences: Major Product Offerings
Table 34 Nano Therapeutics: Major Product Offerings
Table 35 QT Vascular: Major Product Offerings
Table 36 RD Global-Invamed: Major Product Offerings
Table 37 STENTYS: Major Product Offerings
Table 38 Surmodics: Major Product Offerings
Table 39 Terumo: Major Product Offerings
Table 40 Urotronic: Major Product Offerings
Table 41 Wellinq: Major Product Offerings
Table 42 MICELL TECHNOLOGIES: Investigational Product
Table 43 Orchestra BioMed: Major Investigational Products
Table 44 Global Market by Indication 2019−2025 ($ million)
Table 45 Global Market by Indication 2019−2025 (%)
Table 46 Global Market by Drug Type 2019−2025 ($ million)
Table 47 Global Market by Drug Type 2019−2025 (%)
Table 48 Global Market by End-user 2019−2025 ($ million)
Table 49 Global Market by End-user 2019−2025 (%)
Table 50 Global Market by Geography 2019−2025 ($ million)
Table 51 Global Market by Geography 2019−2025 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
